University of Wisconsin–Madison

PRM151

August 2016 to August 2020

Determine the effect size of PRM-151 relative to placebo in change from Baseline to Week 28 in normal lung parenchyma as quantified on high- resolution CT (HRCT) imaging analysis, pooling subjects on a stable dose of pirfenidone or nintedanib with subjects not on other treatment for IPF.

This project led by: Keith Meyer MD